Tips

From Other Journals

Metoprolol Is a Safe Treatment in Patients With Severe CHF



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2002 Mar 15;65(6):1187-1188.

Beta-adrenergic receptor blockers have been shown to reduce morbidity and mortality in patients with mild to moderate congestive heart failure (CHF). Beta-blocker therapy has been shown to reduce the symptoms of heart failure and appears to be well tolerated by these patients. Despite this proven benefit, there is still some concern about use of beta blockers in patients with more severe CHF. The concern is that these agents may actually worsen symptoms and increase mortality. Goldstein and colleagues studied the effect of a beta1-selective beta blocker—metoprolol controlled release/extended release—in the treatment of patients with severe CHF.

The study was a subgroup analysis of the larger MERIT-HF study with 795 enrolled participants. The study group consisted of patients with New York Heart Association (NYHA) Functional class III or IV heart failure and an ejection fraction of less than 25 percent. Those who qualified for the study were randomly assigned to receive placebo or metoprolol, with starting dosages of 12.5 or 25 mg once daily. The dosage was doubled every two weeks up to a target of 200 mg per day or the highest tolerated dosage. The study looked at cardiac morbidity and mortality, hospitalizations, and tolerability of treatment.

The yearly mortality rate in the metoprolol group was reduced by 39 percent compared with the placebo group. In addition, sudden deaths were reduced by 45 percent, and the number of deaths secondary to worsening of heart failure was reduced by 55 percent. The metoprolol group also had fewer hospitalizations and showed improvement in NYHA functional classification. Metoprolol was well tolerated, and fewer persons withdrew from the trial group than from the placebo group.

The authors conclude that metoprolol controlled release/extended release can be used in the treatment of severe CHF. This treatment was well tolerated, reduced mortality rates, and improved heart failure symptoms.

Goldstein S, et al. Metoprolol controlled release/extended release in patients with severe heart failure. Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol. October 2001;38:932–8.



Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article